Paradoxically augmented anti-tumorigenic action of proton pump inhibitor and Gastrin in APCMin/+ intestinal polyposis model

Neoplasia (United States)

Volumn 16, Issue 1, 2014, Pages 73-83

  Han, Young Min ^a,b   Hahm, Ki Baik ^a,c   Park, Jong Min ^a   Hong, Sung Pyo ^c   Kim, Eun Hee ^a,b  

^a CHA University   (South Korea)

^b CHA University   (South Korea)

^c CHA Bundang Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TUBULIN; BETA ACTIN; BETA CATENIN; CD31 ANTIGEN; COMPLEMENTARY DNA; CYCLOOXYGENASE 2; DNA NUCLEOTIDYLEXOTRANSFERASE; GASTRIN; GLYCOGEN SYNTHASE KINASE; LANSOPRAZOLE; LYMPHOID ENHANCER FACTOR 1; OMEPRAZOLE; RABEPRAZOLE; SYNAPTOPHYSIN; T CELL FACTOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RISK; CARCINOGENESIS; CELL CULTURE; CELL CYCLE PHASE; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GASTROINTESTINAL POLYPOSIS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; LUCIFERASE ASSAY; MALE; MOUSE; NICK END LABELING; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SEQUENCE ANALYSIS;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA CATENIN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; GASTRINS; GENE EXPRESSION REGULATION, NEOPLASTIC; INFLAMMATION; INTESTINAL POLYPOSIS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PROTON PUMP INHIBITORS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84900387470     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.131510     Document Type: Article

References (37)

1. Rozengurt E and Walsh JH (2001). Gastrin, CCK, signaling, and cancer. Annu Rev Physiol 63, 49-76
2. Kovac S, Xiao L, Shulkes A, Patel O, and Baldwin GS (2010). Gastrin increases its own synthesis in gastrointestinal cancer cells via the CCK2 receptor. FEBS Lett 584, 4413-4418
3. Hartwich A, Konturek SJ, Pierzchalski P, Zuchowicz M, Labza H, Konturek PC, Karczewska E, Bielanski W, Marlicz K, Starzynska T, et al. (2001). Helicobacter pylori infection, gastrin, cyclooxygenase-2, and apoptosis in colorectal cancer. Int J Colorectal Dis 16, 202-210
4. Robertson DJ, Larsson H, Friis S, Pedersen L, Baron JA, and Sorensen HT (2007). Proton pump inhibitor use and risk of colorectal cancer: a populationbased, case-control study. Gastroenterology 133, 755-760
5. Colucci R, Blandizzi C, Tanini M, Vassalle C, Breschi MC, and Del Tacca M (2005). Gastrin promotes human colon cancer cell growth via CCK-2 receptormediated cyclooxygenase-2 induction and prostaglandin E2 production. Br J Pharmacol 144, 338-348
6. Muerkoster S, Isberner A, Arlt A, Witt M, Reimann B, Blaszczuk E, Werbing V, Folsch UR, Schmitz F, and Schafer H (2005). Gastrin suppresses growth of CCK2 receptor expressing colon cancer cells by inducing apoptosis in vitro and in vivo. Gastroenterology 129, 952-968
7. Parikh N and Howden CW (2010). The safety of drugs used in acid-related disorders and functional gastrointestinal disorders. Gastroenterol Clin North Am 39, 529-542
8. Kedika RR, Souza RF, and Spechler SJ (2009). Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci 54, 2312-2317
9. Kim YJ, Lee JS, Hong KS, Chung JW, Kim JH, and Hahm KB (2010). Novel application of proton pump inhibitor for the prevention of colitis-induced colorectal carcinogenesis beyond acid suppression. Cancer Prev Res (Phila) 3, 963-974
10. Min/+ mice. Cancer Res 63, 895-901
11. Korsisaari N, Kasman IM, Forrest WF, Pal N, Bai W, Fuh G, Peale FV, Smits R, and Ferrara N (2007). Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice. Proc Natl Acad Sci USA 104, 10625-10630
12. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, and Taketo MM (1996). Suppression of intestinal polyposis in ApcΔ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87, 803-809
13. Kim S, Domon-Dell C, Wang Q, Chung DH, Di Cristofano A, Pandolfi PP, Freund JN, and Evers BM (2002). PTEN and TNF-α regulation of the intestinalspecific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-κB-dependent pathway. Gastroenterology 123, 1163-1178
14. Koh TJ, Bulitta CJ, Fleming JV, Dockray GJ, Varro A, and Wang TC (2000). Gastrin is a target of the β-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis. J Clin Invest 106, 533-539
15. Koh TJ and Chen D (2000). Gastrin as a growth factor in the gastrointestinal tract. Regul Pept 93, 37-44
16. Walsh JH (1990). Role of gastrin as a trophic hormone. Digestion 47(suppl 1), 11-16; discussion 49-52
17. Yassin RR (1999). Signaling pathways mediating gastrin's growth-promoting effects. Peptides 20, 885-898
18. Singh P, Owlia A, Espeijo R, and Dai B (1995). Novel gastrin receptors mediate mitogenic effects of gastrin and processing intermediates of gastrin on Swiss 3T3 fibroblasts. Absence of detectable cholecystokinin (CCK)-A and CCK-B receptors. J Biol Chem 270, 8429-8438
19. Bordi C, D'Adda T, Azzoni C, Pilato FP, and Caruana P (1995). Hypergastrinemia and gastric enterochromaffin-like cells. Am J Surg Pathol 19(suppl 1), S8-S19
20. Crean GP, Marshall MW, and Rumsey RD (1969). Parietal cell hyperplasia induced by the administration of pentagastrin (ICI 50,123) to rats. Gastroenterology 57, 147-155
21. McGregor DB, Jones RD, Karlin DA, and Romsdahl MM (1982). Trophic effects of gastrin on colorectal neoplasms in the rat. Ann Surg 195, 219-223
22. Stepan VM, Tatewaki M, Matsushima M, Dickinson CJ, del Valle J, and Todisco A (1999). Gastrin induces c-fos gene transcription via multiple signaling pathways. Am J Physiol 276, G415-G424
23. Yang K, Hitomi M, and Stacey DW (2006). Variations in cyclin D1 levels through the cell cycle determine the proliferative fate of a cell. Cell Div 1, 32
24. Palmero I and Peters G (1996). Perturbation of cell cycle regulators in human cancer. Cancer Surv 27, 351-367
25. Han YM, Park JM, Park SH, Hahm KB, Hong SP, and Kim EH (2013). Gastrin promotes intestinal polyposis through cholecystokinin-B receptor-mediated proliferative signaling and fostering tumor microenvironment. J Physiol Pharmacol 64, 429-437
26. Yang YX, Hennessy S, Propert K, Hwang WT, Sedarat A, and Lewis JD (2007). Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 133, 748-754
27. Burkitt MD, Varro A, and Pritchard DM (2009). Importance of gastrin in the pathogenesis and treatment of gastric tumors. World J Gastroenterol 15, 1-16
28. Reinhardt JD, McCloy RM, and Blackwell CF (1976). Autoimmune atrophic gastritis with hypergastrinemia. South Med J 69, 1551-1553
29. Ibiza S, Alvarez A, Romero W, Barrachina MD, Esplugues JV, and Calatayud S (2009). Gastrin induces the interaction between human mononuclear leukocytes and endothelial cells through the endothelial expression of P-selectin and VCAM-1. Am J Physiol Cell Physiol 297, C1588-C1595
30. Yeo M, Kim DK, Han SU, Lee JE, Kim YB, Cho YK, Kim JH, Cho SW, and Hahm KB (2006). Novel action of gastric proton pump inhibitor on suppression of Helicobacter pylori induced angiogenesis. Gut 55, 26-33
31. Yeo M, Kim DK, Kim YB, Oh TY, Lee JE, Cho SW, Kim HC, and Hahm KB (2004). Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells. Clin Cancer Res 10, 8687-8696
32. Lee HJ, Han YM, Kim EH, Kim YJ, and Hahm KB (2012). A possible involvement of Nrf2-mediated heme oxygenase-1 up-regulation in protective effect of the proton pump inhibitor pantoprazole against indomethacin-induced gastric damage in rats. BMC Gastroenterol 12, 143
33. Stubbs M, McSheehy PM, and Griffiths JR (1999). Causes and consequences of acidic pH in tumors: a magnetic resonance study. Adv Enzyme Regul 39, 13-30
34. Tannock IF and Rotin D (1989). Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 49, 4373-4384
35. Lee AH and Tannock IF (1998). Heterogeneity of intracellular pH and of mechanisms that regulate intracellular pH in populations of cultured cells. Cancer Res 58, 1901-1908
36. + exchange: structure, regulation, and its role in heart disease. Circ Res 85, 777-786
37. + exchangers. Physiol Rev 77, 51-74.